{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:45:18Z","timestamp":1793353518244,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["healthpolicyjrnl.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.healthpol.2014.01.015","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T10:15:42Z","timestamp":1390990542000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Brand loyalty, patients and limited generic medicines uptake"],"prefix":"10.1016","volume":"116","author":[{"given":"Joan","family":"Costa-Font","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rudisill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healthpol.2014.01.015_bib0005","series-title":"Sustainable provision of generic medicines in Europe","author":"Simoens","year":"2013"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1057\/palgrave.jgm.4940128","article-title":"Sustaining generic medicines markets in Europe","volume":"3","author":"Simoens","year":"2006","journal-title":"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0015","series-title":"2011 market review: the European generic medicines markets","author":"Association","year":"2011"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/467257","article-title":"Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act","volume":"35","author":"Grabowski","year":"1992","journal-title":"Journal of Law and Economics"},{"issue":"22","key":"10.1016\/j.healthpol.2014.01.015_bib0025","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1080\/00036846.2012.703313","article-title":"The generics paradox revisited: empirical evidence from regulated markets","volume":"45","author":"Vandoros","year":"2013","journal-title":"Applied Economics"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0030","series-title":"Pricing, patent loss and the market for pharmaceuticals","author":"Frank","year":"1993"},{"issue":"1","key":"10.1016\/j.healthpol.2014.01.015_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1162\/105864097567039","article-title":"Generic entry and the pricing of pharmaceuticals","volume":"6","author":"Frank","year":"1997","journal-title":"Journal of Economics & Management Strategy"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0040","series-title":"Generic scrip share and the price of brand-name drugs: the role of the consumer","author":"Rizzo","year":"2005"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0045","series-title":"The generic drug: numbers and dimensions","author":"Assogenerici","year":"2011"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0050","first-page":"1","article-title":"Spain: health system review","volume":"12","author":"Garcia-Armesto","year":"2010","journal-title":"Health Systems in Transition"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1300\/J371v13n04_04","article-title":"The pharmaceutical market regulation in Spain: is drug cost-containment under question","volume":"13","author":"Costa-Font","year":"2004","journal-title":"Journal of Pharmaceutical Finance, Economics & Policy"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1332\/030557307782452994","article-title":"Institutional change, innovation and regulation failure: evidence from the Spanish drug market","volume":"35","author":"Costa-Font","year":"2007","journal-title":"Policy & Politics"},{"issue":"55","key":"10.1016\/j.healthpol.2014.01.015_bib0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1468-0327.2008.00207.x","article-title":"Competition in off-patent drug markets: issues, regulation and evidence","volume":"23","author":"Kanavos","year":"2008","journal-title":"Economic Policy"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1211\/ijpp\/17.02.0002","article-title":"Consumers\u2019 views on generic medicines: a review of the literature","volume":"17","author":"Hassali","year":"2009","journal-title":"International Journal of Pharmacy Practice"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","article-title":"Patients\u2019 perceptions of generic medications","volume":"28","author":"Shrank","year":"2009","journal-title":"Health Affairs (Millwood)"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0080","series-title":"Behavioural economics and its applications","article-title":"Behavioural economics and health economics","author":"Frank","year":"2007"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2307\/2555818","article-title":"The importance of the physician in the generic versus trade-name prescription decision","volume":"29","author":"Hellerstein","year":"1998","journal-title":"The RAND Journal of Economics"},{"issue":"18","key":"10.1016\/j.healthpol.2014.01.015_bib0090","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/archinte.1997.00440390066010","article-title":"A physician survey on generic drugs and substitution of critical dose medications","volume":"157","author":"Banahan","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0095","series-title":"Comparative Tables on Social Protection in the Member States. Mutual Information System on Social Protection 2013 1 Jan 2013 17 November 2013","author":"MISSOC","year":"2013"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","article-title":"Patients\u2019 perceptions of generic medications","volume":"28","author":"Shrank","year":"2009","journal-title":"Health Affairs"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2165\/00019053-199600102-00017","article-title":"Longer patents for increased generic competition in the US","volume":"10","author":"Grabowski","year":"1996","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2307\/3087468","article-title":"Do pharmaceutical prices respond to potential patient out-of-pocket expenses?","volume":"29","author":"Pavcnik","year":"2002","journal-title":"RAND Journal of Economics"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jhealeco.2008.10.009","article-title":"Financial incentives and physicians\u2019 prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan","volume":"28","author":"Liu","year":"2009","journal-title":"Journal of Health Economics"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0120","series-title":"The evolution of brand preferences: evidence from consumer migration","author":"Bronnenberg","year":"2010"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0167-7187(83)90003-6","article-title":"The advantage of being first and competition between firms","volume":"1","author":"Conrad","year":"1983","journal-title":"International Journal of Industrial Organization"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0130","series-title":"Physicians\u2019 attitudes and practices regarding generic drugs","author":"Barrett","year":"2005"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1211\/ijpp.13.4.0004","article-title":"Generic medicines: perceptions of consumers in Melbourne, Australia","volume":"13","author":"Hassali","year":"2005","journal-title":"International Journal of Pharmacy Practice"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.healthpol.2010.10.015","article-title":"Psychosocial factors associated with the prescription of generic drugs","volume":"101","author":"Rodr\u00edguez-Calvillo","year":"2011","journal-title":"Health Policy"},{"issue":"2","key":"10.1016\/j.healthpol.2014.01.015_bib0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11533030-000000000-00000","article-title":"Citizens\u2019 preferences for brand name drugs for treating acute and chronic conditions","volume":"9","author":"Denoth","year":"2011","journal-title":"Applied Health Economics and Health Policy"},{"issue":"3","key":"10.1016\/j.healthpol.2014.01.015_bib0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10198-012-0377-8","article-title":"Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data","volume":"13","author":"Farfan-Portet","year":"2012","journal-title":"The European Journal of Health Economics"},{"issue":"3","key":"10.1016\/j.healthpol.2014.01.015_bib0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.healthpol.2006.10.006","article-title":"Customers\u2019 and physicians\u2019 opinions of and experiences with generic substitution during the first year in Finland","volume":"82","author":"Heikkil\u00e4","year":"2007","journal-title":"Health Policy (Amsterdam Netherlands)"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/074391569101000211","article-title":"Consumer response to generic\/chemically equivalent drugs","author":"Kendall","year":"1991","journal-title":"Journal of Public Policy & Marketing"},{"issue":"5","key":"10.1016\/j.healthpol.2014.01.015_bib0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11096-006-9043-5","article-title":"Patients\u2019 attitudes towards and experiences of generic drug substitution in Norway","volume":"28","author":"Kjoenniksen","year":"2006","journal-title":"Pharmacy World and Science"},{"issue":"11","key":"10.1016\/j.healthpol.2014.01.015_bib0170","first-page":"1383","article-title":"The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation","volume":"5","author":"Motheral","year":"1999","journal-title":"The American Journal of Managed Care"},{"issue":"3","key":"10.1016\/j.healthpol.2014.01.015_bib0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10389-011-0393-7","article-title":"Community pharmacists\u2019 perspectives on generic substitution in Japan","volume":"19","author":"Kobayashi","year":"2011","journal-title":"Journal of Public Health"},{"issue":"1","key":"10.1016\/j.healthpol.2014.01.015_bib0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.healthpol.2011.10.001","article-title":"Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists","volume":"104","author":"Quintal","year":"2012","journal-title":"Health Policy"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0185","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11096-010-9402-0","article-title":"An evaluation of consumers\u2019 knowledge, perceptions and attitudes regarding generic medicines in Auckland","volume":"32","author":"Babar","year":"2010","journal-title":"Pharmacy World and Science"},{"issue":"3","key":"10.1016\/j.healthpol.2014.01.015_bib0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0168-8510(03)00018-6","article-title":"A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice","volume":"65","author":"Vall\u00e8s","year":"2003","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0195","series-title":"Applied econometrics for health economists: a practical guide","author":"Jones","year":"2007"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0200","first-page":"14","article-title":"Pharmaceutical policy reform in Spain","volume":"12","author":"Costa-Font","year":"2006","journal-title":"Eurohealth \u2013 London"},{"issue":"4","key":"10.1016\/j.healthpol.2014.01.015_bib0205","first-page":"1","article-title":"Portugal: health system review","volume":"13","author":"Barros","year":"2011","journal-title":"Health Systems in Transition"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0210","series-title":"Study on assessment of generic medicines in the Spanish population 2013","author":"AESEG","year":"2013"},{"key":"10.1016\/j.healthpol.2014.01.015_bib0215","series-title":"Consumo de gen\u00e9ricos en Espa\u00f1a [Spanish]","author":"Ministry of Health Social Policy and Equality","year":"2013"},{"issue":"5","key":"10.1016\/j.healthpol.2014.01.015_bib0220","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s11096-008-9247-y","article-title":"People's views on the level of agreement of generic medicines for different illnesses","volume":"30","author":"Figueiras","year":"2008","journal-title":"Pharmacy World and Science"}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851014000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851014000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T16:56:17Z","timestamp":1648140977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851014000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":44,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0168851014000281"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2014.01.015","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brand loyalty, patients and limited generic medicines uptake","name":"articletitle","label":"Article Title"},{"value":"Health Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healthpol.2014.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}